Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Stephen H. Gillespie(University of St Andrews), Andrew Nunn(University College London)
Cited by 653
Related Papers
Perspective for Precision Medicine for Tuberculosis
|Frontiers in Immunology|2020|69
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
|The International Journal of Tuberculosis and Lung Disease|2021|63